您好, 歡迎來到環(huán)保在線! 登錄| 免費(fèi)注冊| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:上海裕平生物科技有限公司>>公司動(dòng)態(tài)>>Blood:白血病細(xì)胞的宿命
來自哈爾濱醫(yī)科大學(xué)附屬*醫(yī)院,哈佛大學(xué)醫(yī)學(xué)院的研究人員發(fā)表了題為“Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells”的文章,證明吞噬作用抑制了急性早幼粒細(xì)胞白血?。ˋPL)細(xì)胞的促凝和纖溶活性,解答了多年來有關(guān)白血病細(xì)胞宿命的相關(guān)問題,這一成果公布在Blood雜志上。
文章的通訊作者是哈佛大學(xué)醫(yī)學(xué)院布萊根婦女醫(yī)院的史家嵐博士,其早年畢業(yè)于哈爾濱醫(yī)科大學(xué),目前在布萊根婦女醫(yī)院血液腫瘤科從事教學(xué)和研究工作,被聘為龍江學(xué)者,哈醫(yī)大一院教授,博士生導(dǎo)師。國家自然科學(xué)基金課題評審專家;Blood, J Thrombosis and Haemostasis, Thrombosis and Haemostasis 審稿人。史家嵐研究組主要從事出凝血方面的研究,包括磷脂酰絲氨酸及凋亡細(xì)胞促凝血和乳粘素抗凝血機(jī)制。
APL是以危及生命的血栓和出血以及早幼粒細(xì)胞的積聚為特征的疾病,盡管這種疾病代表了一種成功治療的范例,在臨床和實(shí)驗(yàn)水平皆取得了明顯的進(jìn)步,但APL細(xì)胞的移除過程仍有待研究。特別是在化療后,損傷的腫瘤細(xì)胞的命運(yùn)和這些細(xì)胞在哪里和怎樣被清除還不清楚,延遲排除這些細(xì)胞將直接導(dǎo)致彌漫性血管內(nèi)凝血及隨后的出血,故治療早期死亡率高。
急性早幼粒細(xì)胞白血病凝血紊亂主要與APL原始細(xì)胞的促凝物質(zhì)和纖溶激活物相關(guān),但是這些白血病細(xì)胞的宿命仍不清楚。
在這項(xiàng)研究中,研究人員探究了MΦ和Ecs在體外對APL細(xì)胞的吞噬作用以及其與APL促凝活性和纖溶活性的相關(guān)性。另外他們還研究了乳粘素在吞噬中的作用,并確定了乳粘素和吞噬具有協(xié)同調(diào)節(jié)APL凝血功能紊亂的作用。結(jié)果顯示:培養(yǎng)的MΦ和Ecs都能吞噬APL細(xì)胞,乳粘素以時(shí)間依賴性的方式促進(jìn)了這種吞食。
這項(xiàng)研究證明了MΦ和ECs在體外對APL細(xì)胞的吞噬作用能夠防止APL的凝血紊亂,乳粘素通過其促進(jìn)吞食APL細(xì)胞的作用或許可以用于減少白血病細(xì)胞數(shù)量,乳粘素和巨噬細(xì)胞具有能夠協(xié)同降低凝血活性的能力,其對PS相關(guān)的凝血功能紊亂有可能是一個(gè)有吸引力的治療策略。并且,乳粘素介導(dǎo)的吞食將有助于改善APL纖溶亢進(jìn)狀態(tài)。
史家嵐研究組還去年還曾報(bào)道其研究組生物探針方面的研究進(jìn)展——他們發(fā)現(xiàn)乳黏素還有望替代目前普遍使用的膜聯(lián)蛋白,用于檢測細(xì)胞凋亡。膜聯(lián)蛋白也是一種PS結(jié)合蛋白,但用于細(xì)胞凋亡檢測時(shí),可被活細(xì)胞吞噬而導(dǎo)致假陽性;膜聯(lián)蛋白與PS結(jié)合須有鈣離子存在,而鈣離子有可能夸大陽性結(jié)果;當(dāng)PS在細(xì)胞表面暴露低于2.5%~8%時(shí),膜聯(lián)蛋白與PS結(jié)合不敏感。相對而言,乳黏素能以非鈣依賴的方式與凋亡細(xì)胞表面暴露的PS結(jié)合,且特異性和敏感性均高于膜聯(lián)蛋白,因此作為檢測細(xì)胞凋亡的探針將很有前景。
(生物通:萬紋)
原文摘要:
Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells
The coagulopathy of acute promyelocytic leukemia (APL) is mainly related to procoagulant substances and fibrinolytic activators of APL blasts, but the fate of these leukemic cells is unknown. The aim of this study was to investigate the removal of APL blasts by macrophages and endothelial cells in vitro and consequent procoagulant and fibrinolytic activity of APL cells. We found that human umbilical vein endothelial cells as well as THP-1 and monocyte-derived macrophages bound, engulfed and subsequently degraded immortalized APL cell line NB4 and primary APL cells. Lactadherin promoted phagocytosis of APL cells in a time-dependent fashion. Furthermore, factor Xa and prothrombinase activity of PS-exposed target APL cells was time-dependently decreased after incubation with phagocytes (THP-1-derived macrophages or human umbilical vein endothelial cells). Thrombin production on target APL cells was reduced by 40-45% after two hours of coincubation with phagocytes, and 80% by a combination of lactadherin and phagocytes. Moreover, plasmin generation of target APL cells was inhibited 30% by two hours of phagocytosis, and approximay 50% by lactadherin-mediated engulfment. These results suggest that engulfment by macrophages and endothelial cells reduce procoagulant and fibrinolytic activity of APL blasts. Lactadherin and phagocytosis could cooperatively ameliorate the clotting disorders in APL.
來源:生物通
請輸入賬號(hào)
請輸入密碼
請輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),環(huán)保在線對此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購買風(fēng)險(xiǎn),建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。